SCHEMBL4028729

SCHEMBL4028729

CC(=O)c1ccc2noc(-c3ccc(N4CCCCC4)cc3)c2c1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 12/20 0.81
IP6K3 Q96PC2 10/20 0.81
IP6K2 Q9UHH9 10/20 0.81
ALDH1A1 P00352 6/20 0.66
KDM4E B2RXH2 4/20 0.66
L3MBTL1 Q9Y468 2/20 0.66
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
NPC1 O15118 2/20 0.62
GAA P10253 1/20 0.56
HTT P42858 1/20 0.56
POLB P06746 2/20 0.53
RAB9A P51151 1/20 0.53
TP53 P04637 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024961 0.91 IP6K1 (0.67) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL25991867 0.89 IP6K1 (1.00) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL4027586 0.79 ALDH1A1 (1.00) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL4033499 0.79 MEN1 (1.00) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL4027834 0.79 ALDH1A1 (1.00) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL31105539 0.78 IP6K1 (0.60) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL4028069 0.78 SMN1; SMN2 (0.67) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL31105851 0.78 IP6K1 (0.62) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL31105870 0.77 IP6K1 (0.64) IP6K1IP6K3IP6K2ALDH1A1KDM4E
SCHEMBL31105842 0.76 IP6K1 (0.59) IP6K1IP6K3IP6K2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399440-B1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2009-06-03 EP disclosed
US-20050228005-A1 Protein kinase inhibitors and uses thereof MOON YOUNG C 2005-10-13 US disclosed
US-6825190-B2 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES VERTEX PHARMACEUTICALS INCORPORATED 2004-11-30 US disclosed
US-20040009996-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009996-A1 Protein kinase inhibitors and uses thereof GSK3A, GSK3B, JAK3 IP6K1 278/4885IP6K3 144/4885IP6K2 334/4885
US-20050228005-A1 Protein kinase inhibitors and uses thereof GSK3A, JAK3, GSK3B IP6K1 363/4885IP6K3 152/4885IP6K2 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.